Posterior Reversible Leukoencephalopathy Syndrome in a patient after second dose of Rituximab for treatment of resistant Thrombotic Thrombocytopenic Purpura
Journal of Clinical Nephrology · 2018
DOI: 10.29328/journal.jcn.1001010 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Nephrology, 2018. Verfasst von Sabaa Asif und 2 weiteren Autor:innen. Die Arbeit nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Posterior reversible encephalopathy syndrome (PRES) is a neurological syndrome with clinical features of altered sensorium, headaches, visual problems and seizures. It has been associated with uncontrolled hypertension (HTN), thrombotic thrombocytopenic purpura (TTP) and immunosuppressive drugs. Rituximab has also been implicated as a cause of PRES that usually occurs after the irst dose. We report a case of PRES that occurred after the second dose of Rituximab. A twenty three years old female known case of resistant TTP treated with multiple courses of steroids and plasmapharesis was admitted with renal failure, severe volume overload ad lower respiratory tract infection. She was treated with hemodialysis, intravenous antibiotics, steroids and plasma exchange (PEX). She did not responded and due to worsening thrombocytopenia and persistent hemolysis was administered Rituximab as an adjunct therapy. She tolerated the irst dose well, however 48 hours after the second dose she developed uncontrolled HTN of 190/110 associated with generalized tonic clonic seizures and altered sensorium requiring intubation and mechanical ventilation. MRI indings were suggestive of PRES. Seizures did not get controlled with conventional therapy and patient underwent two consecutive cycles of PEX to remove the drug which resolved the seizures.
Zitieren
APA
Asif, S., Mahmood, S. N., & Naveed, O. K. (2018). Posterior Reversible Leukoencephalopathy Syndrome in a patient after second dose of Rituximab for treatment of resistant Thrombotic Thrombocytopenic Purpura. Journal of Clinical Nephrology. https://doi.org/10.29328/journal.jcn.1001010
Vancouver
Asif S, Mahmood SN, Naveed OK. Posterior Reversible Leukoencephalopathy Syndrome in a patient after second dose of Rituximab for treatment of resistant Thrombotic Thrombocytopenic Purpura. Journal of Clinical Nephrology. 2018. doi:10.29328/journal.jcn.1001010
BibTeX
@article{Asif2018,
author = {Asif, Sabaa and Mahmood, Sumbal Nasir and Naveed, Osama Kunwer},
title = {Posterior Reversible Leukoencephalopathy Syndrome in a patient after second dose of Rituximab for treatment of resistant Thrombotic Thrombocytopenic Purpura},
journal = {Journal of Clinical Nephrology},
year = {2018},
doi = {10.29328/journal.jcn.1001010}
}
EUVIMED